Trial Profile
Immunogenicity and Safety of GSK Biologicals' DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503) in Healthy Indian Infants
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary)
- Indications Diphtheria; Influenza B virus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 22 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Sep 2017 Planned End Date changed from 30 May 2018 to 1 Aug 2018.
- 26 Sep 2017 Planned primary completion date changed from 30 May 2018 to 1 Aug 2018.